{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:01:48Z","timestamp":1791284508104,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,12]]},"abstract":"<jats:p>Gardner et al report that early intervention with tocilizumab and steroids at the first signs of mild cytokine release syndrome (CRS) following CD19 chimeric antigen receptor (CAR) T-cell infusion for B-cell acute lymphocytic leukemia reduces the development of life-threatening severe CRS without having a negative impact on antileukemic effect.<\/jats:p>","DOI":"10.1182\/blood.2019001463","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T19:19:06Z","timestamp":1571080746000},"page":"2149-2158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":270,"title":["Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy"],"prefix":"10.1182","volume":"134","author":[{"given":"Rebecca A.","family":"Gardner","sequence":"first","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceppi","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rivers","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Annesley","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1769-7388","authenticated-orcid":false,"given":"Corinne","family":"Summers","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Taraseviciute","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Gust","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Neurology, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7905-6714","authenticated-orcid":false,"given":"Kasey J.","family":"Leger","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tarlock","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia C.","family":"Finney","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Brakke","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Statistics Group, Juno Therapeutics, Inc., Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Park","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute, Seattle, WA;"},{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2019121211522960800_B1","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019121211522960800_B2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2019121211522960800_B3","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2019121211522960800_B4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"2019121211522960800_B5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019121211522960800_B6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"12","key":"2019121211522960800_B7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"2019121211522960800_B8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"9967","key":"2019121211522960800_B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"2019121211522960800_B10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"2","key":"2019121211522960800_B11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published corrections appear in Blood. 2015;126(8):1048 and Blood. 2016;128(11):1533]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019121211522960800_B12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019121211522960800_B13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"224","key":"2019121211522960800_B14","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"2019121211522960800_B15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","article-title":"Glucocorticoids in T cell apoptosis and function","volume":"63","author":"Herold","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"303","key":"2019121211522960800_B16","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"24","key":"2019121211522960800_B17","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019121211522960800_B18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-012-1378-2","article-title":"Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails","volume":"62","author":"Yang","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2019121211522960800_B19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jcyt.2013.10.013","article-title":"Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy","volume":"16","author":"Barrett","year":"2014","journal-title":"Cytotherapy"},{"key":"2019121211522960800_B20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"2019121211522960800_B21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40259-018-0324-z","article-title":"Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities","volume":"33","author":"Dholaria","year":"2019","journal-title":"BioDrugs"},{"issue":"5","key":"2019121211522960800_B22","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"16","key":"2019121211522960800_B23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2019121211522960800_B24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019121211522960800_B25","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity [published correction appears in Proc Natl Acad Sci USA. 2019;116(22):11075-11076]","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019121211522960800_B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6123(10)82001-1","article-title":"Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes","volume":"182","author":"Smith","year":"2010","journal-title":"Prog Brain Res"},{"key":"2019121211522960800_B27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019121211522960800_B28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/24\/2149\/1547430\/bloodbld2019001463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/24\/2149\/1547430\/bloodbld2019001463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T19:20:10Z","timestamp":1664652010000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/24\/2149\/381162\/Preemptive-mitigation-of-CD19-CAR-Tcell-cytokine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001463","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]}}}